ArticleLeukemia & lymphoma2015
Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.
Article in Leukemia & lymphoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma.Journal of veterinary internal medicine · 2026Article
- Article
- Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.PloS one · 2025Article
- Review
- Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy.Scientific reports · 2022Article
- Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.The Journal of veterinary medical science · 2021Article
- Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody.The Biochemical journal · 2021Article
- Flow Cytometry in the Diagnosis of Canine B-Cell Lymphoma.Frontiers in veterinary science · 2021Review
- Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma.Frontiers in veterinary science · 2021Review
- T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma.Frontiers in veterinary science · 2021Article
- Deep pemphigus (pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus) in dogs, cats and horses: a comprehensive review.BMC veterinary research · 2020Review
- Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.BMC veterinary research · 2019Article
- Article
- ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).PloS one · 2017Article
- Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.Cancer immunology research · 2016Article
- Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine.PloS one · 2016Article
- Canine cancer immunotherapy studies: linking mouse and human.Journal for immunotherapy of cancer · 2016Review
- Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure.Veterinary sciences · 2015Article
- A double blinded, placebo-controlled pilot study to examine reduction of CD34F1000Research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In humans, passive immunotherapy with anti-CD20 monoclonal antibodies (mAbs) has created immeasurable improvements in outcomes of patients with B-cell malignancies. However, the lack of comparable reagents has precluded development of this approach in dogs. We developed a novel anti-canine CD20 mAb designated as 6C8. 6C8 recognized the extracellular domain of canine CD20 and showed high-affinity binding to canine CD20 in solution, as well as in its native conformation on canine B-cells. The 6C8 target was expressed invariably in B-cell lineage cells, but not in T-cells or myeloid cells. 6C8 promoted phagocytosis of B-cell lymphoma cells by macrophages, but in its current framework, it did not induce direct cytotoxicity or complement dependent cytotoxicity. In summary, we have established a novel anti-canine CD20 mAb that is useful as a diagnostic tool to phenotype B-cells, and which could be integrated as a tool for passive immunotherapy to treat dogs with B-cell disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.